Last reviewed · How we verify
Iohexol Injection
At a glance
| Generic name | Iohexol Injection |
|---|---|
| Also known as | OMNIPAQUE |
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care (NA)
- The Practicality and Utility of Measured vs Estimated GFR in adCKD
- Iohexol Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance (NA)
- MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure (NA)
- Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer (EARLY_PHASE1)
- Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study (PHASE3)
- STA363 in the Treatment of Lumbar Disc Herniation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iohexol Injection CI brief — competitive landscape report
- Iohexol Injection updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI